Review on Treatment of Gout & Hyperuricemia
DOI:
https://doi.org/10.3329/jbcps.v29i2.7953Abstract
In the last few decades, both hyperuricemia and gout have increased markedly. Recent studies show new concept into the transporters that handle uric acid in the kidney as well as possible links between these transporters & hyperuricemia. There are changes in the treatment of established hyperuricemia. Febuxostat and PEGuricase are two novel treatments that have been evaluated and shown to be highly effective in the management of hyperuricemia. Monosodium urate (MSU) crystals are the inducers of inflammation. Within the joint, they trigger a local inflammatory reaction, neutrophil recruitment, and the production of proinflammatory cytokines as well as other inflammatory mediators. The uptake of MSU crystals by monocytes involves interactions with components of the innate immune system. The inflammatory effects of MSU are IL-1-dependent and can be blocked by IL-1 inhibitors. These advances in the understanding of hyperuricemia and gout provide new therapeutic targets for the future.
DOI: http://dx.doi.org/10.3329/jbcps.v29i2.7953
(J Bangladesh Coll Phys Surg 2011; 29: 85-95)
Downloads
268
151
Downloads
How to Cite
Issue
Section
License
Submission of a manuscript for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted manuscripts become the permanent property of the Journal of Bangladesh College of Physicians and Surgeons and may not be reproduced by any means in whole or in part without the written consent of the publisher.
No part of the materials published in this journal may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher. Reprints of any article in the Journal will be available from the publisher.